Is FTV a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Fortive Corporation (FTV) rests on Recurring revenue and software mix: Roughly half of Fortive's revenue is recurring, spread across software (Accruent, Gordian, ServiceChannel, Provation) and consumables (ASP sterilization). Revenue (TTM, post-spin) is ~$4.1B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Fortive trades at a premium valuation (a trailing P/E in the low-to-mid 30s), so any growth disappointment or multiple compression could pressure the stock. Whether FTV is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Fortive Corporation is a technology solutions company that was itself spun out of Danaher in 2016 and has since used the Danaher-style operating playbook to build recurring-revenue businesses. In June 2025 it completed the spin-off of its Precision Technologies segment as Ralliant (RAL), which took brands like Tektronix and specialty sensors with it, leaving Fortive with two segments. Intelligent Operating Solutions (IOS) is anchored by the Fluke test-and-measurement brand plus facilities and asset-management software (Accruent, Gordian, ServiceChannel). Advanced Healthcare Solutions (AHS) covers hospital sterilization and infection prevention (ASP) and clinical workflow software (Provation, Censis). The investment picture centers on quality and recurring revenue: roughly half of sales are recurring, adjusted EBITDA margins sit near 29 percent, and the company generates strong free cash flow that funds buybacks and bolt-on acquisitions. Q1 2026 showed revenue around $1.07 billion (up ~7.7 percent) with mid-single-digit core growth and about 25 percent adjusted EPS growth. The trade-off is valuation: FTV trades at a premium earnings multiple, so returns depend on continued margin expansion, capital deployment, and durable end-market demand rather than a cheap entry point.
What's the case for buying FTV?
1. Recurring revenue and software mix
Roughly half of Fortive's revenue is recurring, spread across software (Accruent, Gordian, ServiceChannel, Provation) and consumables (ASP sterilization). This mix supports margin durability and more predictable growth than a pure hardware instruments business, and management continues to push the software and services attach rate higher.
2. Margin expansion via the Fortive Business System
The company runs a Danaher-style continuous-improvement operating system. In Q1 2026 adjusted EBITDA margin expanded about 140 basis points to roughly 29 percent, with the healthcare segment up over 200 basis points. Ongoing productivity and pricing are central to the earnings-growth thesis.
3. Capital deployment and M&A
Fortive throws off substantial free cash flow (about $194 million in Q1 2026) that funds share repurchases (~$500 million in the quarter) and bolt-on acquisitions. As a now-simpler two-segment company, it has flexibility to redeploy capital into recurring-revenue targets that fit its playbook.
4. Post-spin focus and simplification
The Ralliant separation left a more focused business with higher recurring revenue and stronger margins than the pre-spin conglomerate. A cleaner story and a new CEO (Olumide Soroye) give management a mandate to re-rate the portfolio around IOS and AHS growth trends.
What are the risks to FTV?
Fortive trades at a premium valuation (a trailing P/E in the low-to-mid 30s), so any growth disappointment or multiple compression could pressure the stock. Its industrial end markets are cyclical and exposed to manufacturing, construction and facilities spending, which can soften in a downturn. The healthcare segment faces hospital capital-spending cycles and competitive infection-prevention alternatives. Serial acquisitions carry integration and goodwill-impairment risk, and the recent spin-off adds comparability noise to reported results. Currency and global supply-chain costs can also swing margins quarter to quarter.
How is FTV valued? (as of July 2026)
Snapshot for FTV as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM, post-spin): ~$4.1B
- Q1 2026 revenue: ~$1.07B (up ~7.7% YoY)
- Adjusted EBITDA margin: ~29%
- Adjusted EPS (Q1 2026): ~$0.70 (up ~25% YoY)
- 2026 adjusted EPS guidance: ~$2.90-$3.00
- Market cap: ~$17-18B
- Trailing P/E: ~32x
After the Ralliant spin-off, Fortive's continuing-operations revenue base is roughly $4 billion, smaller than the pre-spin company but higher-margin. The premium P/E in the low-to-mid 30s reflects the market pricing in recurring revenue and steady compounding rather than a bargain. Forward multiples look lower on expected earnings growth.
How do you decide if FTV is a buy?
Rather than asking whether FTV is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold FTV indirectly through an index or sector ETF before adding more.
For the full picture, see the FTV stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about FTV against your real portfolio and see your actual exposure before deciding.
The bottom line on FTV
The bottom line: Fortive Corporation's story right now is Recurring revenue and software mix, with revenue (ttm, post-spin) at ~$4.1B. If you believe that narrative continues, the call is about sizing FTV sensibly and checking overlap with what you own; if you doubt it (the risk: fortive trades at a premium valuation (a trailing P/E in the low-to-mid 30s), so any growth disappointment or multiple compression could pressure the stock.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around FTV with Walnut
Use Fortive Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is FTV a good stock to buy right now?
+
The case for Fortive Corporation right now is Recurring revenue and software mix, with revenue (ttm, post-spin) at ~$4.1B. If you believe that thesis holds, FTV is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is fortive trades at a premium valuation (a trailing P/E in the low-to-mid 30s), so any growth disappointment or multiple compression could pressure the stock. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Fortive Corporation do?
+
Fortive Corporation is a technology solutions company that was itself spun out of Danaher in 2016 and has since used the Danaher-style operating playbook to build recurring-revenue
What are the main risks of FTV?
+
Fortive trades at a premium valuation (a trailing P/E in the low-to-mid 30s), so any growth disappointment or multiple compression could pressure the stock. Its industrial end markets are cyclical and exposed to manufacturing, construction and facilities spending, which can soften in a downturn. The healthcare segment faces hospital capital-spending cycles and competitive infection-prevention alternatives. Serial acquisitions carry integration and goodwill-impairment risk, and the recent spin-off adds comparability noise to reported results. Currency and global supply-chain costs can also swing margins quarter to quarter.
What does Fortive (FTV) do?
+
Fortive is an industrial technology company with two segments: Intelligent Operating Solutions (Fluke test tools plus facilities and asset software like Accruent, Gordian and ServiceChannel) and Advanced Healthcare Solutions (ASP sterilization and clinical software like Provation and Censis). About half its revenue is recurring.
Did Fortive spin off part of the company?
+
Yes. In June 2025 Fortive completed the spin-off of its Precision Technologies segment as Ralliant Corporation (NYSE: RAL), which included brands such as Tektronix and specialty sensors. Fortive shareholders received one Ralliant share for every three Fortive shares. Fortive continues to trade as FTV.
Is Tektronix still part of Fortive?
+
No. Tektronix moved to Ralliant as part of the Precision Technologies spin-off in mid-2025. Fortive's remaining perimeter is the IOS and AHS segments, anchored by Fluke, Accruent, ASP and Provation, not Tektronix.
How did Fortive perform in its most recent quarter?
+
In Q1 2026 Fortive reported revenue of about $1.07 billion, up roughly 7.7 percent year over year with mid-single-digit core growth. Adjusted EPS was about $0.70, up roughly 25 percent, and adjusted EBITDA margin expanded to near 29 percent.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell FTV; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.